Samuel Cheshier – Special Presentation: Stanford Childx Conference

TL;DR

A new therapy that blocks CD47 protein on cancer cells can allow macrophages to eat and destroy them, sparing normal cells, and shows promise in treating various types of cancer.

Transcript

[MUSIC PLAYING] Today, I'm going to talk to you about a therapy that has been developed entirely at this institution. And the main researcher in this is my mentor, Dr. Irving Weissman. And this has been developed completely at this institution from beginning to end. So this is truly from the bench to the bedside. And I happen to be in charge of the... Read More

Key Insights

• 🥺 Cancer is the leading cause of death in children, and current treatments have severe and permanent side effects.
• 🧠 Brain tumors in children are challenging to treat due to their location and resistance to traditional therapies.
• ♋ The immune system can recognize cancer cells as non-self and attack them, making the immune system a potential target for cancer therapy.
• 👻 Anti-CD47 therapy blocks the CD47 protein on cancer cells, allowing macrophages to recognize and destroy them while sparing normal cells.
• 🧠 Preclinical studies have demonstrated the efficacy of this therapy against various cancers, including pediatric brain tumors.
• ⛔ The therapy has no dose-limiting toxicity and is currently undergoing clinical trials.
• 🇦🇬 Combination therapies with other immune therapies are being explored to enhance the effectiveness of anti-CD47 therapy.

Questions & Answers

Q: Why are current cancer treatments especially detrimental to pediatric patients?

Current cancer treatments, such as chemotherapy and radiation, have severe and permanent side effects, including cognitive dysfunction, organ damage, and nerve damage. These effects are particularly harmful to young patients who may experience a lifetime of disabilities and an increased risk of secondary cancers later in life.

Q: How are brain tumors in children different from those in adults?

Brain tumors in children are often inoperable and resistant to traditional therapies. They occur in very young patients who cannot tolerate intensive irradiation and chemotherapies. This makes brain tumors in children more difficult to treat and requires specific therapies targeted at the central nervous system.

Q: Why is blocking the CD47 protein on cancer cells significant?

Blocking the CD47 protein on cancer cells allows macrophages in the immune system to recognize and destroy these cells specifically. This therapy spares normal cells from harm, making it a promising treatment option that can be more effective and less toxic than traditional treatments.

Q: What are the potential benefits of anti-CD47 therapy?

Anti-CD47 therapy has shown potent activity against various types of cancer, including pediatric brain tumors. It has no dose-limiting toxicity and has been well-tolerated in preclinical studies. Clinical trials are currently ongoing, and the therapy has the potential to revolutionize cancer treatment by reducing the need for radiation and chemotherapy.

Summary & Key Takeaways

• Cancer treatment options such as surgery, chemotherapy, and radiation have severe and permanent side effects, particularly in pediatric patients.

• Brain tumors in children are often inoperable and resistant to traditional therapies, making them difficult to treat.

• The immune system's ability to recognize and destroy cancer cells has led to the development of an anti-CD47 therapy that allows macrophages to attack and eliminate cancer cells specifically.

• In preclinical studies, the therapy has successfully eradicated various types of cancer, including pediatric brain tumors, with no significant toxicity observed.

• Clinical trials are currently underway, and the therapy shows potential as a more effective and less harmful treatment option for cancer patients.